JP2015525211A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015525211A5 JP2015525211A5 JP2015514525A JP2015514525A JP2015525211A5 JP 2015525211 A5 JP2015525211 A5 JP 2015525211A5 JP 2015514525 A JP2015514525 A JP 2015514525A JP 2015514525 A JP2015514525 A JP 2015514525A JP 2015525211 A5 JP2015525211 A5 JP 2015525211A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- polypeptide
- cdr1
- cdr2
- cdr3
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001184 polypeptide Polymers 0.000 claims 43
- 108090000765 processed proteins & peptides Proteins 0.000 claims 42
- 102000004196 processed proteins & peptides Human genes 0.000 claims 42
- 108060003951 Immunoglobulin Proteins 0.000 claims 27
- 102000018358 immunoglobulin Human genes 0.000 claims 27
- 101710189965 P2X purinoceptor 7 Proteins 0.000 claims 17
- 102100037602 P2X purinoceptor 7 Human genes 0.000 claims 17
- 125000003275 alpha amino acid group Chemical group 0.000 claims 11
- 150000001413 amino acids Chemical class 0.000 claims 11
- 101001098175 Homo sapiens P2X purinoceptor 7 Proteins 0.000 claims 6
- 230000000890 antigenic effect Effects 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 238000012216 screening Methods 0.000 claims 2
- 102000008100 Human Serum Albumin Human genes 0.000 claims 1
- 108091006905 Human Serum Albumin Proteins 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical group 0.000 claims 1
- 239000002773 nucleotide Chemical group 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261654417P | 2012-06-01 | 2012-06-01 | |
| US61/654,417 | 2012-06-01 | ||
| PCT/EP2013/061257 WO2013178783A1 (en) | 2012-06-01 | 2013-05-31 | P2x7 receptor antagonists and agonists |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018108470A Division JP6681433B2 (ja) | 2012-06-01 | 2018-06-06 | Ｐ２ｘ７受容体アンタゴニスト及びアゴニスト |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015525211A JP2015525211A (ja) | 2015-09-03 |
| JP2015525211A5 true JP2015525211A5 (cg-RX-API-DMAC7.html) | 2016-07-21 |
| JP6608698B2 JP6608698B2 (ja) | 2019-11-27 |
Family
ID=48579032
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015514525A Active JP6608698B2 (ja) | 2012-06-01 | 2013-05-31 | Ｐ２ｘ７受容体アンタゴニスト及びアゴニスト |
| JP2018108470A Active JP6681433B2 (ja) | 2012-06-01 | 2018-06-06 | Ｐ２ｘ７受容体アンタゴニスト及びアゴニスト |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018108470A Active JP6681433B2 (ja) | 2012-06-01 | 2018-06-06 | Ｐ２ｘ７受容体アンタゴニスト及びアゴニスト |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US9908935B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2855518A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP6608698B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN104507964B (cg-RX-API-DMAC7.html) |
| AU (2) | AU2013269606B2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2013178783A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102257003B (zh) | 2008-12-19 | 2017-04-05 | 埃博灵克斯股份有限公司 | 用于产生针对细胞相关抗原如p2x7、cxcr7或cxcr4的免疫球蛋白的基因免疫 |
| WO2013178783A1 (en) | 2012-06-01 | 2013-12-05 | Ablynx N.V. | P2x7 receptor antagonists and agonists |
| US10071167B2 (en) | 2013-05-08 | 2018-09-11 | Children's Medical Center Corporation | Method of preventing and treating type 1 diabetes, allograft rejection and lung fibrosis (by targeting the ATP/P2X7R axis) |
| RS63085B1 (sr) | 2014-05-16 | 2022-04-29 | Ablynx Nv | Varijabilni domeni imunoglobulina |
| IL318433A (en) | 2014-05-16 | 2025-03-01 | Ablynx Nv | Improved immunoglobulin variable complexes |
| AU2016240410B2 (en) * | 2015-04-02 | 2021-09-16 | Biosceptre (Aust) Pty Ltd | Pain treatment |
| JP7403224B2 (ja) * | 2015-11-12 | 2023-12-22 | アブリンクス エン．ヴェー． | 改良されたｐ２ｘ７受容体結合剤およびこれを含むポリペプチド |
| PL233352B1 (pl) * | 2016-09-15 | 2019-10-31 | Adamed Spolka Z Ograniczona Odpowiedzialnoscia | Przeciwnowotworowe białko fuzyjne |
| CN109321589A (zh) * | 2018-10-15 | 2019-02-12 | 潍坊医学院 | 一种制备p2x7r免疫原的方法 |
| CN110054691B (zh) * | 2019-05-09 | 2021-09-07 | 潍坊医学院 | 一种抗人p2rx7单克隆抗体的杂交瘤细胞系 |
| JP2022548499A (ja) * | 2019-08-23 | 2022-11-21 | ユーエヌエム レインフォレスト イノベーションズ | 非オピオイド組成物及び疼痛管理のための治療法 |
| US20240009180A1 (en) | 2020-11-30 | 2024-01-11 | Asahi Kasei Pharma Corporation | Medicine for alleviating neuropathic pain |
| TW202440614A (zh) | 2022-12-23 | 2024-10-16 | 比利時商艾伯霖克斯公司 | 基於蛋白質的接合載體 |
| WO2024170756A1 (en) | 2023-02-17 | 2024-08-22 | Ablynx N.V. | Polypeptides binding to the neonatal fc receptor |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004090097A2 (en) * | 2003-04-03 | 2004-10-21 | Bristol-Myers Squibb Company | Polynucleotide encoding a novel human p2x7 splice variant, hbmyp2x7v |
| US8124730B1 (en) * | 2004-04-02 | 2012-02-28 | Bristol-Myers Squibb Company | Polynucleotide encoding a novel human P2X7 splice variant, HBMYP2X7v |
| CN102257003B (zh) * | 2008-12-19 | 2017-04-05 | 埃博灵克斯股份有限公司 | 用于产生针对细胞相关抗原如p2x7、cxcr7或cxcr4的免疫球蛋白的基因免疫 |
| WO2013178783A1 (en) | 2012-06-01 | 2013-12-05 | Ablynx N.V. | P2x7 receptor antagonists and agonists |
-
2013
- 2013-05-31 WO PCT/EP2013/061257 patent/WO2013178783A1/en not_active Ceased
- 2013-05-31 JP JP2015514525A patent/JP6608698B2/ja active Active
- 2013-05-31 EP EP13727838.8A patent/EP2855518A1/en active Pending
- 2013-05-31 AU AU2013269606A patent/AU2013269606B2/en active Active
- 2013-05-31 CN CN201380040371.6A patent/CN104507964B/zh active Active
- 2013-05-31 US US14/403,754 patent/US9908935B2/en active Active
-
2018
- 2018-01-19 US US15/874,938 patent/US10544216B2/en active Active
- 2018-06-06 JP JP2018108470A patent/JP6681433B2/ja active Active
- 2018-08-14 AU AU2018217239A patent/AU2018217239B2/en active Active